Bio-Path (NASDAQ:BPTH – Get Free Report) issued its earnings results on Wednesday. The company reported ($1.16) earnings per share for the quarter, topping the consensus estimate of ($1.54) by $0.38, Yahoo Finance reports. During the same quarter last year, the business earned ($10.60) EPS.
Bio-Path Trading Down 0.7 %
BPTH stock opened at $1.48 on Friday. The company’s 50 day simple moving average is $1.82 and its 200-day simple moving average is $3.67. Bio-Path has a 12 month low of $1.31 and a 12 month high of $21.60.
Analyst Upgrades and Downgrades
Several research analysts have weighed in on BPTH shares. Roth Mkm restated a “buy” rating and set a $20.00 target price on shares of Bio-Path in a research report on Monday, July 8th. StockNews.com initiated coverage on shares of Bio-Path in a research report on Thursday, May 2nd. They set a “sell” rating on the stock.
Bio-Path Company Profile
Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.
Featured Stories
- Five stocks we like better than Bio-Path
- What Is WallStreetBets and What Stocks Are They Targeting?
- Bumble’s Valuation Hits an All-Time Low, Can Its Fortunes Change?
- EV Stocks and How to Profit from Them
- MarketBeat Week in Review – 8/12 – 8/16
- The Risks of Owning Bonds
- JD.com Earnings Surprise: China’s Outlook Better Than Expected
Receive News & Ratings for Bio-Path Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Path and related companies with MarketBeat.com's FREE daily email newsletter.
